Q4 sales again exceeded expectations, driven by GLP-1 products and obesity care offerings, which overshadowed insulins’ weakness. With all doses for Wegovy available from December 2022 onwards, obesity care should get a further impetus. For 2023, strong growth and higher capex, to meet increasing demand, are guided by management. Overall, despite being a quality stock, Novo seems expensive, especially given the looming competitive risks and interest rate hikes (possibly) nearing a peak resulting ....
03 Feb 2023
Yet another strong quarter + healthy guidance, but remains expensive
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Yet another strong quarter + healthy guidance, but remains expensive
- Published:
03 Feb 2023 -
Author:
Abhishek Raval -
Pages:
4
Q4 sales again exceeded expectations, driven by GLP-1 products and obesity care offerings, which overshadowed insulins’ weakness. With all doses for Wegovy available from December 2022 onwards, obesity care should get a further impetus. For 2023, strong growth and higher capex, to meet increasing demand, are guided by management. Overall, despite being a quality stock, Novo seems expensive, especially given the looming competitive risks and interest rate hikes (possibly) nearing a peak resulting ....